Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
- PMID: 27530235
- PMCID: PMC4987691
- DOI: 10.1038/srep31727
Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
Abstract
Corticosteroids are extensively used in pediatrics, yet the burden of side effects is significant. Availability of a simple, fast, and reliable biochemical read out of steroidal drug pharmacodynamics could enable a rapid and objective assessment of safety and efficacy of corticosteroids and aid development of corticosteroid replacement drugs. To identify potential corticosteroid responsive biomarkers we performed proteome profiling of serum samples from DMD and IBD patients with and without corticosteroid treatment using SOMAscan aptamer panel testing 1,129 proteins in <0.1 cc of sera. Ten pro-inflammatory proteins were elevated in untreated patients and suppressed by corticosteroids (MMP12, IL22RA2, CCL22, IGFBP2, FCER2, LY9, ITGa1/b1, LTa1/b2, ANGPT2 and FGG). These are candidate biomarkers for anti-inflammatory efficacy of corticosteroids. Known safety concerns were validated, including elevated non-fasting insulin (insulin resistance), and elevated angiotensinogen (salt retention). These were extended by new candidates for metabolism disturbances (leptin, afamin), stunting of growth (growth hormone binding protein), and connective tissue remodeling (MMP3). Significant suppression of multiple adrenal steroid hormones was also seen in treated children (reductions of 17-hydroxyprogesterone, corticosterone, 11-deoxycortisol and testosterone). A panel of new pharmacodynamic biomarkers for corticosteroids in children was defined. Future studies will need to bridge specific biomarkers to mechanism of drug action, and specific clinical outcomes.
Figures



Similar articles
-
Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149418 Free PMC article.
-
Glucocorticoid corticosteroids for Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003725. doi: 10.1002/14651858.CD003725.pub3. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2016 May 05;(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. PMID: 18254031 Updated.
-
Glucocorticoid corticosteroids for Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2004;(2):CD003725. doi: 10.1002/14651858.CD003725.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003725. doi: 10.1002/14651858.CD003725.pub3. PMID: 15106215 Updated.
-
Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.Cochrane Database Syst Rev. 2021 Dec 1;12(12):CD013720. doi: 10.1002/14651858.CD013720.pub3. Cochrane Database Syst Rev. 2021. PMID: 34850383 Free PMC article.
-
Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.Cochrane Database Syst Rev. 2021 Nov 8;11(11):CD013720. doi: 10.1002/14651858.CD013720.pub2. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2021 Dec 1;12:CD013720. doi: 10.1002/14651858.CD013720.pub3. PMID: 34748221 Free PMC article. Updated.
Cited by
-
Insulin-Like Growth Factor Binding Proteins in Autoimmune Diseases.Front Endocrinol (Lausanne). 2018 Aug 30;9:499. doi: 10.3389/fendo.2018.00499. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30214426 Free PMC article. Review.
-
Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.Steroids. 2018 Jun;134:43-52. doi: 10.1016/j.steroids.2018.02.010. Epub 2018 Mar 8. Steroids. 2018. PMID: 29524454 Free PMC article. Clinical Trial.
-
Associations of 2923 plasma proteins with incident inflammatory bowel disease in a prospective cohort study and genetic analysis.Nat Commun. 2025 Mar 21;16(1):2813. doi: 10.1038/s41467-025-57879-3. Nat Commun. 2025. PMID: 40118817 Free PMC article.
-
Joint Fluid Proteome after Anterior Cruciate Ligament Rupture Reflects an Acute Posttraumatic Inflammatory and Chondrodegenerative State.Cartilage. 2020 Jul;11(3):329-337. doi: 10.1177/1947603518790009. Epub 2018 Jul 22. Cartilage. 2020. PMID: 30033738 Free PMC article.
-
Serum protein biomarker signature of Duchenne muscular dystrophy.Eur J Transl Myol. 2025 Jun 27;35(2):13956. doi: 10.4081/ejtm.2025.13956. Epub 2025 May 28. Eur J Transl Myol. 2025. PMID: 40438995 Free PMC article.
References
-
- Hillier S. G. Diamonds are forever: the cortisone legacy. The Journal of endocrinology 195, 1–6 (2007). - PubMed
-
- Swartz S. L. & Dluhy R. G. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 16, 238–255 (1978). - PubMed
-
- Kapadia C. R. et al.. Endocrine Effects of Inhaled Corticosteroids in Children. JAMA Pediatr 170, 163–170 (2016). - PubMed
-
- von Scheven E., Corbin K. J., Stagi S. & Cimaz R. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep 12, 289–299 (2014). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous